What is the safest way to taper and discontinue aripiprazole (Abilify) and bupropion (Wellbutrin) used for negative symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 23, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Discontinuing Aripiprazole and Bupropion for Negative Symptoms

Both aripiprazole and bupropion should be tapered gradually rather than stopped abruptly, with bupropion requiring a slower taper over several weeks and aripiprazole typically tapered over 1–2 weeks, while monitoring closely for withdrawal symptoms and return of psychiatric symptoms.


Critical Safety Framework

Abrupt discontinuation of either medication can cause withdrawal symptoms and symptom rebound. While neither medication carries the life-threatening withdrawal risks of benzodiazepines or opioids, both require careful tapering to minimize discomfort and psychiatric destabilization 1, 2.

  • Bupropion withdrawal can cause irritability, anxiety, insomnia, headache, and generalized aches and pains when stopped abruptly 1.
  • Antipsychotic discontinuation (including aripiprazole) risks re-emergence of psychotic symptoms and discontinuation reactions 3.
  • The taper rate must be determined by the patient's tolerance, not a rigid schedule, and pauses are acceptable when withdrawal symptoms emerge 4.

Recommended Tapering Protocol

Bupropion Discontinuation

Taper bupropion by reducing the dose by 25–50% every 1–2 weeks, extending the taper over 4–6 weeks minimum for patients on long-term therapy.

  • For bupropion SR 150 mg twice daily (300 mg total), reduce to 150 mg once daily for 1–2 weeks, then to 150 mg every other day for 1 week before stopping 5, 2.
  • For bupropion XL 300 mg once daily, reduce to 150 mg once daily for 2 weeks, then stop 5.
  • Patients on higher doses (e.g., 450 mg/day) require more gradual reductions: decrease by 150 mg every 1–2 weeks 5.
  • Very conservative tapering schedules may be needed for some individuals to prevent re-emergence of withdrawal symptoms 2.

Monitor for withdrawal symptoms: irritability, anxiety, insomnia, headache, mood changes, and generalized aches 1, 2.

  • Most withdrawal reactions are mild and short-lived, requiring only patient reassurance 2.
  • Severe cases can be managed by reinstating the antidepressant at the previous dose (symptoms typically resolve within 24 hours) and then tapering more slowly 2.

Aripiprazole Discontinuation

Taper aripiprazole over 1–2 weeks using a cross-taper or gradual dose reduction approach.

  • For aripiprazole 10–15 mg daily, reduce to 5 mg daily for 1 week, then stop 3.
  • For higher doses (20–30 mg), reduce by 5–10 mg every 3–7 days 3.
  • Cross-tapering is generally the most acceptable method: gradually reduce aripiprazole while monitoring for symptom re-emergence 3.

Monitor for discontinuation reactions: anxiety, agitation, insomnia, nausea, and return of negative symptoms or psychotic features 3.

  • Abrupt withdrawal may be necessary only if the patient develops a severe or acute reaction to current treatment 3.
  • Most patients (87%) in one study switched antipsychotics without problems, but this included both abrupt and tapered approaches 3.

Sequencing: Which to Taper First?

Taper both medications simultaneously using a cross-taper approach, or taper aripiprazole first over 1–2 weeks, then begin tapering bupropion.

  • There is no pharmacological interaction requiring one to be stopped before the other 5.
  • Tapering aripiprazole first may be preferable if the patient has significant negative symptoms, as bupropion's activating properties may help maintain energy and motivation during the antipsychotic taper 5.
  • If the patient has prominent anxiety or agitation, consider tapering bupropion first to reduce activating effects 5.

Monitoring Requirements

Follow up at least every 1–2 weeks during the taper, with more frequent contact during difficult phases.

  • Assess for withdrawal symptoms: irritability, anxiety, insomnia, headache, mood changes, nausea, and agitation 1, 2.
  • Monitor for return of negative symptoms: apathy, anhedonia, social withdrawal, and reduced motivation 3.
  • Screen for depression, anxiety, and suicidal ideation, particularly in patients under 24 years 5, 6.
  • The risk for suicide attempts is greatest during the first 1–2 months of treatment changes 5.

Patient Education and Support

Educate patients about potential withdrawal symptoms and the importance of not stopping medications abruptly.

  • Explain that withdrawal symptoms are temporary and typically resolve within days to weeks 2.
  • Advise patients to contact their provider if withdrawal symptoms become severe or if psychiatric symptoms worsen 2.
  • Preventative strategies include tapering antidepressants prior to stoppage and educating patients to ensure medications are taken consistently and not stopped abruptly 2.

When to Pause or Slow the Taper

Clinically significant withdrawal symptoms signal the need to further slow the taper rate or pause entirely.

  • If moderate-to-severe withdrawal symptoms emerge, hold at the current dose for 1–2 weeks before resuming the taper 4, 2.
  • Severe psychological distress (depression, panic attacks, suicidal ideation) warrants pausing the taper 7.
  • Some individuals require very conservative tapering schedules to prevent re-emergence of symptoms 2.

Management of Withdrawal Symptoms

Most withdrawal reactions are mild and require only reassurance; severe cases may require reinstatement and slower taper.

  • For mild symptoms (irritability, headache, insomnia): provide reassurance and symptomatic treatment (e.g., NSAIDs for headache, trazodone 25–50 mg for insomnia) 7, 2.
  • For severe symptoms: reinstate the medication at the previous dose (symptoms usually resolve within 24 hours), then taper more slowly 2.
  • Reinstatement usually leads to symptom resolution within 24 hours 2.

Special Considerations

Patients with Recurrent Depression or Psychosis

  • Patients with recurrent episodes are at higher risk for relapse during discontinuation 8.
  • Consider maintaining one or both medications if negative symptoms return during the taper 8.
  • Nearly all data on antidepressant discontinuation come from people with recurrent depression 8.

Older Adults

  • Use more gradual tapers (reduce by 25% every 2 weeks instead of weekly) to minimize adverse effects 7.
  • Monitor closely for cognitive changes, falls, and confusion 7.

Patients with Substance Use History

  • Bupropion may be particularly beneficial for patients with comorbid substance use (e.g., nicotine, methamphetamine) 5.
  • Consider maintaining bupropion if substance use is a concern 5.

Critical Pitfalls to Avoid

  • Never stop either medication abruptly without medical supervision 1, 2.
  • Do not confuse withdrawal symptoms with relapse of depression or psychosis—withdrawal symptoms typically emerge within days of dose reduction and resolve with reinstatement 8, 2.
  • Do not abandon the patient if tapering is unsuccessful—maintenance therapy is a legitimate outcome 4, 7.
  • Do not taper too quickly—most tapering regimens in studies lasted 4 weeks or less, which may increase withdrawal risk 8.

Expected Timeline

  • Bupropion taper: 4–6 weeks minimum for standard doses; longer for higher doses or long-term use 5, 2.
  • Aripiprazole taper: 1–2 weeks for most patients 3.
  • Total discontinuation process: 6–8 weeks when tapering both medications sequentially 8, 2.

Alternative Approach: Switching vs. Discontinuing

If negative symptoms return during the taper, consider switching to alternative treatments rather than complete discontinuation.

  • For persistent negative symptoms, consider switching aripiprazole to another antipsychotic with better efficacy for negative symptoms 3.
  • For depression with low energy, consider maintaining bupropion or switching to an SSRI 4, 5.
  • Switching to another medication may be preferable to complete discontinuation if symptoms re-emerge 3.

References

Research

Bupropion-Associated Withdrawal Symptoms: A Case Report.

Primary care companion to the Journal of clinical psychiatry, 1999

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Bupropion Dosing and Administration

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Benzodiazepine Discontinuation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

How should I safely taper my patient off Pristiq (desvenlafaxine)?
How should I taper bupropion (Wellbutrin) 300 mg daily in an adult?
Can discontinuation of Wellbutrin (bupropion) cause depression?
Does atomoxetine (Strattera) require a taper when discontinuing?
What is the recommended tapering schedule for a patient taking 150mg of Wellbutrin (bupropion) daily?
What is the likely diagnosis and appropriate workup and management for an 18‑year‑old male who has a tender suprascrotal area above the right testicle, orange cloudy urine with bilirubin and protein, and reports semen passage during a bowel movement?
What is the differential diagnosis and recommended workup for a 56‑year‑old postmenopausal woman with a one‑month history of intermittent flushing and dizziness, normal inflammatory markers, normal thyroid function, hypokalemia, normal 5‑hydroxyindoleacetic acid and urine metanephrines, and a postmenopausal hormone profile?
What next‑line treatments are recommended for chronic burning pruritus that is refractory to duloxetine (Cymbalta) and pregabalin (Lyrica)?
What is the typical starting dose of intramuscular testosterone (testosterone enanthate or cypionate) for an adult woman?
What probiotic strain(s), dose, and duration are recommended for otherwise healthy patients aged three years and older with antibiotic‑associated diarrhea or mild irritable bowel syndrome, and what safety precautions should be considered?
What are the typical symptoms, diagnostic workup, and initial management of aspiration pneumonia in an older adult with risk factors such as neurologic impairment, alcohol abuse, or impaired consciousness?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.